Cancer classification using the Immunoscore: a worldwide task force
Inserm · Laboratoire d’immunologie intégrative du cancer · +63 more institutions
Abstract
Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N) and evidence for metastases (M). However, it is now recognized that clinical outcome can significantly vary among patients within the same stage. The current classification provides limited prognostic information, and does not predict response to therapy. Recent literature has alluded to the importance of the host immune system in controlling tumor progression. Thus, evidence supports the…
Citation impact
- FWCI
- 24.93
- Percentile
- 100%
- References
- 40
Authors
64- JGJérôme GalonCorresponding
Inserm, Laboratoire d’immunologie intégrative du cancer
- FPFranck Pagès
Délégation Paris 5, Inserm, Université Paris Cité, Sorbonne Université, Centre de Recherche des Cordeliers, Assistance Publique – Hôpitaux de Paris, Laboratoire d’immunologie intégrative du cancer
- FMFrancesco M. Marincola
Society for Immunotherapy of Cancer, National Institutes of Health Clinical Center
- HKHelen K. Angell
Délégation Paris 5, Inserm, Université Paris Cité, Sorbonne Université, Centre de Recherche des Cordeliers, Laboratoire d’immunologie intégrative du cancer
- MTMagdalena Thurin
National Institutes of Health, National Cancer Institute
Topics & keywords
- Medicine
- Oncology
- Cancer
- Biomarker
- Immune system
- Internal medicine
- Immunology
- Peace, Justice and strong institutions